P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk (NCT06468033)
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk. Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.
Who can join: Review the eligibility criteria below.
Location: USC Norris Comprehensive Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (73 Sites)
Showing the first 25 of 73 sites.
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Georgetown University Medical Center — Washington D.C., District of Columbia
- University of Kansas Medical Center (KUMC) — Kansas City, Kansas
- American Oncology Partners of Maryland PA (Center for Cancer and Blood Disorders) — Bethesda, Maryland
- Washington University School of Medicine — St Louis, Missouri
- Weill Medical College of Cornell University — New York, New York
- Stony Brook University Medical Center — Stony Brook, New York
- Levine Cancer Institute — Charlotte, North Carolina
- Duke University — Durham, North Carolina
- Ohio State University — Columbus, Ohio
- MD Anderson Cancer Center — Houston, Texas
- Virginia Commonwealth University — Richmond, Virginia
- University of Washington Medical Center - Fred Hutchinson Cancer Center — Seattle, Washington
- St. Michael's Hospital — Toronto, Ontario
- Princess Margaret Hospital — Toronto, Ontario
- Jewish General Hospital — Montreal, Quebec
- Peking Union Medical College Hospital — Beijing, Beijing Municipality
- Peking University People's Hospital — Beijing, Beijing Municipality
- The Second Affiliated Hospital of AMU — Chongqing, Chongqing Municipality
- Southern Hospital of Southern Medical University — Guangdong, Guangdong
- Guangdong Provincial People's Hospital — Guangzhou, Guangzhou
- Institute of Hematology and Oncology, Harbin The First Hospital — Harbin, Heilongjiang
- Henan Cancer Hospital — Zhengzhou, Henan
- Union Hospital Tong Ji Medical College — Wuhan, Hubei
- Jiangsu Provincial Hospital — Nanjing, Jiangsu
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Myelofibrosis
- CINC424A2X01B Rollover Protocol — Darlinghurst, New South Wales
- Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis — Seattle, Washington
- Study of Canakinumab in Patients With Myelofibrosis — Los Angeles, California
- Decitabine in Treating Patients With Myelofibrosis — Chicago, Illinois
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Birmingham, Alabama
Explore by condition: All Primary Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.